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correlates with its incidence in the general population; in
immigrant populations, it is more reﬂective of the countries of
origin. Either way, the incidence of tuberculosis in TRs is higher
than in the general population, with differences by type of
transplant [3,5–8]. One Spanish study showed an annual
tuberculosis incidence of 512 cases per 100 000 TRs (lung
transplant recipients showed the highest incidence (2072/
100 000 patients)), as compared with 19 cases/100 000 persons
in the general population [6].
Tuberculosis remains one of the most serious post-
transplant infections, with mortality rates of 10–40%
[1,2,5,7–11]. Despite recently published guidelines for the
management of post-transplant tuberculosis [12–15], the
diagnosis and treatment of tuberculosis after transplantation
remain challenging, because of the potential side effects of
antituberculous agents and interactions with immunosuppres-
sive drugs [2,3,16–21].
No previous studies have compared tuberculosis in TRs with
tuberculosis in other immunocompromised or immunocom-
petent hosts. Although tuberculosis in TRs is considered to
have a different presentation and a worse outcome than
tuberculosis in the general population, possible differences are
not well characterized.
The aim of this study was to compare the characteristics and
outcomes of tuberculosis in TRs and in patients from the
general population.Materials and methodsSetting, study design, and patients
This study was conducted at the Hospital Clínic Universitari, a
tertiary-care university hospital in Barcelona with active organ
transplantation programmes, including kidney, kidney–pancreas,
liver, heart and haematopoietic stem cell transplantation.
We used a retrospective matched cohort study to compare
clinical features and outcomes of tuberculosis in patients who
had received (transplant cohort) or had not received (control
cohort) a solid organ or stem cell transplant. All patients had a
deﬁnitive tuberculosis diagnosis established by isolation of
Mycobacterium tuberculosis (from any clinical sample).
Patients were identiﬁed from clinical microbiology labora-
tory and transplantation programme databases. We included all
TRs who were culture-positive for tuberculosis diagnosed from
January 1996 through December 2010. Non-TRs were selected
from a list of all patients with culture-positive diagnoses of
tuberculosis in our centre during the same period. For each
year of the study, the order of the list of culture-positive
tuberculosis diagnoses was randomized. Every TR withClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecttuberculosis on the list was paired with the next four tuber-
culosis patients (the non-TRs) who fulﬁlled the matching
criteria, namely, human immunodeﬁciency virus (HIV)-negative
patients who had not received a transplant, matched further
according to gender, age (±2 years), and year of tuberculosis
diagnosis. HIV patients were excluded because of the speciﬁc
characteristics of tuberculosis in this patient group as compared
with HIV-negative patients [22].
Throughout the study period, any hospitalized or ambulatory
patient with suspicion of tuberculosis was tested at our centre;
most patients diagnosed with tuberculosis in primary-care
centres in the area were also referred to our hospital, where
M. tuberculosis cultures were repeated. Any patient with active
tuberculosis was treated and followed up by tuberculosis ex-
perts in the Infectious Diseases Service for at least the duration
of tuberculosis treatment.
Clinical data and deﬁnitions
Data were obtained from the patient’s medical records with a
standard case report form. Variables collected for all patients
included: demographic features; underlying conditions; Charlson
comorbidity score [23]; date of onset of tuberculosis symptoms;
clinical presentation and radiographic ﬁndings; tuberculin skin
test (TST) results; procedures used to obtain a deﬁnitive
tuberculosis diagnosis; time to diagnosis; number of sites with
tuberculosis involvement; type and number of antituberculous
drugs prescribed; antituberculous drug-related toxicity; length
of follow-up following tuberculosis diagnosis; date of last follow-
up and status of the patient at that time; and date and cause of
death during follow-up, if appropriate. For TRs, the following
information was recorded: type of transplant and date; pre-
transplant TST tests; clinical and/or radiological evidence of
pre-transplant tuberculosis; treatment of latent infection; and
time to tuberculosis diagnosis after transplantation.
Information collected about the presence of other well-
known factors predisposing to tuberculosis (excluding trans-
plantation) included: diabetes mellitus, chronic renal failure/
haemodialysis, silicosis, gastrectomy, jejunoileal bypass, hae-
matological malignancies, carcinoma of the head or neck,
alcohol consumption, and therapy with corticosteroids (pred-
nisone or prednisone equivalent administered at >15 mg/day
for 1 month) or other immunosuppressive agents [24–26].
TST results were interpreted according to American
Thoracic Society and CDC recommendations [27]. Organ
involvement by tuberculosis was considered to be deﬁnite if
M. tuberculosis was isolated from the organ, and probable when
patients with a conﬁrmed tuberculosis diagnosis had acid-fast
bacilli smear and/or histopathological ﬁndings consistent with
tuberculosis, and/or signs/symptoms highly suggestive of
tuberculosis involvement (with no alternative diagnosis) thatious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 651–658
TABLE 1. Baseline characteristics of transplant recipients with
active tuberculosis infection
Characteristic Value
Mean age in years (SD) 47 (15)
Male gender, no. (%) 17 (77.3)
Transplant type, no. (%)
Solid organ transplant 17 (77.3)
Kidney 10 (45.5)
Kidney–pancreas 4 (18.2)
Liver 2 (9.1)
Heart 1 (4.5)
Haematopoietic stem cell transplant 5 (22.7)
Allogenic stem cell transplant 2 (9.1)
Autologous stem cell transplant 3 (13.6)
Prior tuberculin skin test performed, no. (%)a 10 (50)
Exposure to tuberculosis before transplantation, no.(%)b 6 (27.3)
Prior positive tuberculin skin test result 2 (20)c
Clinical and/or radiological evidence of prior tuberculosis 5 (22.7)
Radiographic ﬁndings consistent with prior tuberculosis 2 (9.1)
History of prior tuberculosis 4 (18.2)
Treatment of latent tuberculosis infection, no. (%)d 1 (5.3)
Median duration (months) of follow-up (IQR) 50 (70)
Median time (months) from transplantation to diagnosis of
tuberculosis (IQR)
15 (51)
Diagnosis of tuberculosis within 1 year of transplantation, no. (%) 11 (50)
IQR, interquartile range; SD, standard deviation.
aData on tuberculin skin tests were available for 20 patients.
bOne patient had a positive tuberculin test result and a previous history of
tuberculosis.
cPercentage of positive results in patients with a tuberculin skin test.
dData on treatment of latent tuberculosis infection were available for 19 patients.
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classiﬁed as pulmonary (deﬁnitive parenchymal pulmonary
involvement), extrapulmonary (deﬁnitive involvement of other
organs), or disseminated (M. tuberculosis was isolated from two
or more non-contiguous organs or from blood) [1,6]. Hepa-
totoxicity of antituberculous drugs was established when
alanine aminotransferase levels were 3 times the upper limit
of normal in the presence of symptoms, or 5 times the upper
limit of normal in the absence of symptoms [28,29]. Other drug
toxicity was considered when a drug was discontinued because
of adverse effects. Crude mortality was deﬁned as all deaths
occurring during tuberculosis treatment. Mortality was
considered to be tuberculosis-related when death occurred
during treatment with no other apparent cause, and/or in-
vestigators considered tuberculosis to be the main cause of
death. A post-mortem diagnosis of tuberculosis was made when
positive microbiology results became known after the patient
died.
Statistical analysis
Continuous variables were described as means and standard
deviations, or medians and interquartile ranges, depending on
homogeneity. Categorical variables were expressed as abso-
lute frequencies and percentages. Matching was taken into
account in all statistical analyses. Mantel–Haenszel matched-
pairs analysis and the Wilcoxon test were used to assess
group differences for continuous and categorical variables,
respectively. Kaplan–Meier curves were used for survival
analysis, and the log-rank test was used to compare
tuberculosis-related mortality in the transplant and control
cohorts. The Cox proportional hazards model with stratiﬁ-
cation on matched pairs was used to calculate adjusted hazard
ratios and determine whether tuberculosis-related mortality
differed between the two groups, with adjustment for clinically
relevant covariates. All statistical tests were two-tailed;
p-values of <0.05 were considered to be signiﬁcant. Data
analyses were performed with SPSS for Windows version 16
(SPSS, Chicago, IL, USA).ResultsBaseline characteristics of TRs with tuberculosis
Twenty-two TRs (all from Spain) were diagnosed with culture-
positive tuberculosis during the study period. Table 1 shows the
characteristics of the patients. One patient received treatment
for latent infection; no information was available on total length
of treatment and/or degree of compliance. All transplanted
organs were from cadaveric donors, with no identiﬁed or
suspected cases of donor-transmitted tuberculosis [30].Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyComorbid conditions and clinical characteristics of
tuberculosis in TRs and non-TRs
Table 2 compares the underlying conditions of TRs and non-TRs.
More TRs than non-TRs had Charlson scores of 2. Overall,
most TRs (21, 95.5%) and a lower percentage of non-TRs (33,
37.5%; p <0.001) had factors predisposing to active tuberculosis
(excluding transplantation and immunosuppressive drugs).
Alcohol consumption was more common in non-TRs.
The most common presenting symptoms in both patient
cohorts were fever, constitutional symptoms, and cough
(Table 3), although more TRs had fever and symptoms/signs of
extrapulmonary disease. Pulmonary tuberculosis was the
commonest form of disease in both groups, although it was
more common in non-TRs; disseminated tuberculosis was
more common in TRs.
TRs had a higher percentage of normal chest radiographs
than non-TRs. One-third of TRs with radiographic abnormal-
ities and none of the non-TRs had diffuse inﬁltrates. Chest ra-
diographs showing cavitary inﬁltrates were common in the non-
TRs; no TR showed cavitary inﬁltrates.
Diagnosis and treatment of tuberculosis in TRs and
non-TRs
The TST for suspected active tuberculosis was positive in 16
(84.2%) non-TRs and in none of the TRs (p 0.022) (Table 4).
A tuberculosis diagnosis was clinically suspected in 18 (90%)
TRs and in 78 (89.7%) non-TRs (p 0.718). The time from
clinical suspicion to diagnosis (positive acid-fast bacilli smear,and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 651–658
TABLE 2. Underlying conditions and risk factors for tuberculosis in transplant recipients and patients from the general population,
matched by age, gender, and year of tuberculosis diagnosis
Variable
Transplant recipients
(n [ 22), no. (%)
Patients from the general
population (n [ 88), no. (%) RR (95% CI) p
Comorbid condition
Chronic renal failure 13 (59.1) 2 (2.3) 51 (6.48–401.11) <0.001
Diabetes mellitus 6 (27.3) 6 (6.8) 4 (1.25–12.84) 0.008
Haematological neoplasm 5 (22.7) 0 (0) — <0.001
Chronic hepatopathy 2 (9.1) 6 (6.8) 1.5 (0.22–10.08) 0.695
Alcohol consumption 1 (4.5) 26 (29.5) 0.08 (0.01–0.73) 0.043
Chronic pulmonary disease 0 (0) 10 (11.4) — 0.216
Other diseases 3 (13.6)a 2 (2.3)b 6 (1.01–35.91) 0.025
Corticosteroid therapyc 17 (85.3) 3 (15) 96.33 (21–441.84) <0.001
Other immunosuppressive therapy 22 (100) 0 (0) — <0.001
Any comorbid condition 22 (100) 43 (48.9) — <0.001
Charlson score 2 20 (90.9) 8 (9.1) 64.49 (8.60–483.67) <0.001
Factors predisposing to tuberculosis
(excluding transplantation and immunosuppressive
drugs other than corticosteroids)d
21 (95.5) 33 (37.5) 34.8 (4.50–272.42) <0.001
RR, risk ratio.
aOther diseases included: systemic lupus erythematosus, amyloidosis, and ischaemic heart disease.
bOther diseases included: head and neck cancer and Crohn’s disease.
cPrednisone (or prednisone equivalent) administered at >15 mg/day for 1 month.
dWell-known factors predisposing to tuberculosis included here are: diabetes mellitus, chronic renal failure/haemodialysis, silicosis, gastrectomy, jejunoileal bypass, haematological
malignancies, head or neck carcinoma, alcohol consumption and therapy with corticosteroids (prednisone or equivalent administered at >15 mg/day for 1 month). Other
established risk factors for tuberculosis not included here are: other immunosuppressive agents (different from corticosteroids), transplantation, and human immunodeﬁciency virus
infection.
TABLE 3. Clinical characteristics of tuberculosis in transplant recipients and patients from the general population, matched by age,
gender, and year of tuberculosis diagnosis
Characteristics
Transplant recipients
(n [ 22), no. (%)
Patients from the general population
(n [ 88), no. (%) RR (95% CI) p
Clinical manifestations
Fever 17 (81) 42 (49.4) 8.5 (1.81–39.81) 0.002
Constitutional symptomsa 9 (45) 54 (63.5) 0.57 (0.22–1.48) 0.207
Cough 9 (45) 53 (62.4) 0.6 (0.21–1.49) 0.245
Dyspnoea 1 (5) 13 (15.3) 0.27 (0.03–2.41) 0.396
Pleuritic chest pain 1 (5) 15 (17.6) 0.4 (0.05–3.04) 0.287
Haemoptysis 1 (5) 23 (27.1) 0.11 (0.01–1.11) 0.070
Symptoms suggestive of epididymo-orchitis 3 (15)b 0 (0) — 0.004
Monoarticular or oligoarticular pain 2 (10) 1 (1.2) 8 (1.01–88.22) 0.043
Dysphonia 1 (5) 4 (4.7) 1 (0.08–12.56) 1.000
Other clinical manifestations 5 (25)c 4 (4.7)d 9 (1.57–51.74) 0.004
Physical ﬁndings 13 (65) 27 (31.4) 5.33 (1.55–18.39) 0.007
Ascites 7 (35)e 0 (0) — <0.001
Findings consistent with epididymo-orchitis 3 (15)b 0 (0) — 0.004
Monoarthritis or oligoarthritis 2 (10) 1 (1.2) 8 (1.01–88.22) 0.043
Rales on chest examination 1 (5) 14 (16.3) 0.29 (0.04–2.04) 0.346
Findings consistent with pleural effusion 1 (5) 3 (3.5) 2 (0.18–22.06) 0.564
Peripheral lymphadenopathy 1 (5) 8 (9.3) 0.43 (0.04–4.29) 0.861
Tuberculosis form
Pulmonary 12 (54.5) 77 (87.5) 0.12 (0.03–0.44) 0.001
Extrapulmonary 5f (22.7) 7g (8) 3.17 (0.94–10.70) 0.055
Disseminated 5h (22.7) 4i (4.5) 6.33 (1.29–31.11) 0.005
Number of involved organs
Two or more organs involved with a deﬁnitive diagnosis 4 (18.2) 3 (3.4) 6.30 (1.30–30.60) 0.045
Two or more organs involved with a probable diagnosis 8 (36.4) 10 (11.4) 5.40 (1.64–17.77) 0.003
Chest radiograph ﬁndings
None 6 (28.6) 5 (5.7) 5.75 (1.57–21.02) 0.003
Unilateral vs. bilateral pulmonary inﬁltratesj 10 (66.7) 44 (56.4) 1.55 (0.48–4.95) 0.653
Cavitary inﬁltratesj 0 (0) 50 (64.1) — <0.001
Diffuse inﬁltrates vs. focal inﬁltratesj 5 (33.3) 0 (0) — <0.001
Pleural effusion 1 (5) 3 (3.5) 2 (0.181–22.156) 0.571
RR, risk ratio.
aConstitutional symptoms include weight loss, fatigue and/or night sweats.
bTuberculous epididymitis was evaluated and conﬁrmed in two of these patients.
cThree patients with ascites reported progressive abdominal distension; one patient with a psoas abscess reported back pain; and one patient with a brain abscess presented with
neurological symptoms.
dTwo patients with central nervous system disease reported neurological symptoms; one patient with tuberculous spondylitis (Pott’s disease) reported back pain; and one patient
with tuberculosis of the urinary tract reported symptoms of cystitis.
eTuberculous peritonitis was conﬁrmed in two of these patients.
fOrgans involved: urinary tract (two patients), lymph nodes (one patient), brain (one patient), and peritoneum (one patient).
gOrgans involved: lymph nodes (two patients), urinary tract (one patient), larynx (one patient), vertebral bones (one patient), psoas (one patient), and meninges (one patient).
hOrgans involved: lung and blood (one patient), joint and peritoneum (one patient), lung, liver and bone marrow (one patient), lung and psoas (one patient), and lung and testicle (one
patient).
iOrgans involved: lung and peripheral lymph nodes (three patients), and lung and meninges (one patient).
jAll 15 cases (100%) and 78 of 82 controls (95.1%) with radiographic abnormalities had pulmonary inﬁltrates (p 0.868).
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TABLE 4. Diagnosis and treatment of tuberculosis in transplant recipients and patients from the general population, matched by
age, gender, and year of tuberculosis diagnosis
Variable
Transplant recipients
(n [ 22)
Patients from the general
population (n [ 88) RR (95% CI) p
Diagnosis of tuberculosis
Median time (days) from onset of symptoms to diagnosis (IQR) 70 (48) 46 (70) — 0.076
Median time (days) from clinical suspicion of tuberculosis to deﬁnitive diagnosis (IQR) 14 (51.5) 0 (1.25) — 0.001
Sputum culture performed, no. (%) 12 (54.5) 77 (87.5) 0.17 (0.06–0.49) <0.001
Positive sputum culture, no. (%) 10 (83.3) 70 (90.9) 0.5 (0.09–2.75) 0.769
Invasive procedures required, no. (%) 12 (54.5)a 15 (17)b 5.84 (2.14–15.98) 0.001
Post-mortem diagnosis, no. (%) 3 (13.6)c 0 (0) — <0.001
Positive tuberculin skin test result when tuberculosis was suspected, no. (%)d 0 (0) 16 (84.2) — 0.022
Treatment of tuberculosis
Initial isoniazid-containing regimen, no. (%) 19 (100) 88 (100) — —
Initial rifampin-containing regimen, no. (%) 14 (73.7) 88 (100) — <0.001
Initial pyrazinamide-containing regimen, no. (%) 14 (73.7) 85 (93.1) 0.21 (0.06–0.77) 0.037
Initial ethambutol-containing regimen, no. (%) 16 (88.9) 69 (79.3) 2.09 (0.44–9.92) 0.542
Initial quinolone-containing regimen, no. (%) 2 (10.5) 7 (8) 1.35 (0.26–7.05) 0.918
Initial regimen of three drugs, no. (%) 12 (63.2) 22 (25.3) 5.07 (1.77–14.48) 0.004
Initial regimen of four or more drugs 7 (36.8) 65 (74.7) 0.30 (0.07–0.56) 0.004
Median duration (months) of tuberculosis treatment (IQR)e 18 (8.5) 6 (3) — 0.012
Drug toxicity, no. (%) 6 (37.5)f 7 (9.6)g 5.66 (1.58–20.29) 0.014
Hepatotoxicity 4 (25) 6 (8.2) 3.72 (0.91–15.19) 0.139
RR, risk ratio.
aThe most common procedure performed was bronchoscopy with bronchoalveolar lavage (six patients); in the other six patients, biopsy specimens were obtained from different
organs.
bThe most common procedures performed were bronchoscopy with bronchoalveolar lavage (seven patients), biopsy of the lung (two patients), and biopsy of the lymph nodes (two
patients); in the remaining four patients, biopsy specimens were obtained from different organs.
cA positive Mycobacterium tuberculosis culture result was obtained after death in three patients, and one patient was diagnosed only at necropsy (brain abscess culture).
dThe tuberculin skin test was performed when tuberculosis was suspected in three of 19 transplant recipients (15.8%) (information was unavailable in three cases), and in 19 of 86
patients from the control cohort (22.1%) (information was unavailable for two controls) (p 0.766).
ePatients who did not die before the end of the planned treatment.
fFour patients had hepatotoxicity leading to discontinuation of rifampin; in addition, one of these patients also had hyperuricaemia that led to discontinuation of pyrazinamide, one
patient had severe arthralgia and myalgia that led to discontinuation of pyrazinamide, and one patient developed optic neuritis secondarily to ethambutol treatment.
gSix patients developed hepatotoxicity that led to discontinuation of rifampin, isoniazid, or both; one patient had drug fever that led to discontinuation of rifampin.
TABLE 5. Multivariate risk factors for tuberculosis-related
death in transplant recipients and patients from the general
population with tuberculosis
Risk factor
Adjusted hazard ratio
(95% CI) p
Transplantation 1.11 (0.06–21.43) 0.943
Age (years) 1.58 (0.38–6.51) 0.529
Charlson comorbidity score 2 8.03 (0.32–203.41) 0.206
Number of organs with tuberculosis
involvement
10.14 (1.06–97.16) 0.045
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cation test, or M. tuberculosis culture) was longer in TRs, who
more often required invasive procedures. Three TRs (13.6%)
and no non-TRs were diagnosed post-mortem (p <0.05).
Differences in tuberculosis treatment between the cohorts
included the following: TRs were less likely to receive an initial
rifampin-containing or pyrazinamide-containing regimen, and
had a longer duration of antituberculous therapy. TRs had a
higher rate of antituberculous drug toxicity.
Antituberculous drug resistance was observed in three non-
TRs: two with isoniazid-resistant strains of M. tuberculosis, and
the other with a strain resistant to isoniazid and rifampin. After
the initial therapy had been changed, the patients were cured.
The initial antituberculous regimen was appropriate in all other
patients.
Outcomes and risk factors for tuberculosis-related
mortality
No statistically signiﬁcant differences in crude mortality were
found within 30 days (three TRs (13.6%) vs. seven non-TRs
(8%); p 0.411) or 90 days (four TRs (18.2%) vs. eight non-
TRs (9.1%); p 0.217) of tuberculosis diagnosis. Tuberculosis-
related mortality was higher among TRs (four patients,
18.2%) than among non-TRs (ﬁve patients, 5.7%), but the dif-
ference was not statistically signiﬁcant (p 0.057).
No TRs and two non-TRs with tuberculosis relapsed (2.5%;
p 0.68); one patient diagnosed with pulmonary tuberculosis didClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologynot complete the initial 6-month regimen, and relapsed 5 years
later; the other had Pott’s disease, and relapsed 10 months after
completing a 12-month period of treatment. All other patients
were considered to be cured.
After adjustment for previous transplantation, age, Charlson
comorbidity score, and number of organs with probable
tuberculosis involvement, the only independent predictor of
tuberculosis-related mortality was having more organs with
tuberculosis involvement (Table 5).DiscussionThe characteristics and outcomes of tuberculosis in TRs and
non-TRs have not been directly compared before. We
compared TRs and patients from the general population, and
found that the factors predisposing to tuberculosis (other thanand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 651–658
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the cohorts. Having more organs with tuberculosis involve-
ment—which was more common in TRs—was associated with
higher tuberculosis-related mortality.
The risk of tuberculosis in TRs depends mainly on the
endemicity in the geographical area, the transplanted organ
(lung transplant recipients are at highest risk), and the level of
immunosuppression [13]. We additionally found that well-
established risk factors for active tuberculosis in other pop-
ulations [12,24,26], except for alcohol abuse, were much more
common in TRs than in the general population.
In previous reports, extrapulmonary or disseminated
tuberculosis accounted for almost half of post-transplant
tuberculosis cases [1,2,5,9]. Remarkably, we found that the
incidence of disseminated tuberculosis was six times higher in
TRs than in non-TRs. Consequently, more TRs had fever and
diverse manifestations of extrapulmonary disease. To improve
early diagnosis and help prevent mortality in TRs, we think that
tuberculosis should be considered in any TR with fever of un-
known origin [3]. Mycobacterial cultures should also be
routinely considered when any infectious complication or
atypical ﬁnding is evaluated in this population [3].
Most active tuberculosis infections in adult patients,
including TRs, are due to reactivation of latent infections. Most
patients show chest radiograph abnormalities, which are
characteristically parenchymal opacities in upper lobes, often
with cavitation [27,31]. This was the most common radio-
graphic pattern in patients from the general population,
whereas almost 30% of TRs had no radiographic abnormalities
and none had cavitary lesions. However, tuberculosis should
be suspected in TRs with diffuse inﬁltrates, as one-third had
this radiographic pattern.
Along with its atypical presentation, post-transplant tuber-
culosis resists early recognition and diagnosis, because invasive
procedures are often necessary for a deﬁnitive diagnosis to be
made [2,3,14]. We also observed that the deﬁnitive diagnosis
took longer to reach in TRs than in the general population,
supporting the importance of an early, aggressive approach to
diagnosis.
Measurement of the cell-mediated immune response to
M. tuberculosis is the accepted indirect method of detecting
possible infection [13]; the TST is the standard measurement
method. Like previous studies, we found that the TST was an
imperfect identiﬁer of tuberculosis infection in transplant can-
didates and TRs [1,2,32]. Moreover, the TST failed to detect
tuberculosis in any TR with active infection, although it was
positive in >80% of patients from the general population. Some
studies have suggested that interferon-γ release assays are
more sensitive than the TST in transplant candidates and TRs
[33–36]. Unfortunately, neither of the tests is infallible inClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdiagnosing M. tuberculosis infection, or distinguishes between
active and latent tuberculosis [13,14,19,37].
Current guidelines recommend similar tuberculosis treat-
ment in TRs and immunocompetent hosts [12–14]. Spanish
guidelines, however, recommend the avoidance of rifamycins in
non-severe cases, because they reduce the levels of some
immunosuppressive drugs, increasing the risk of graft rejection
[12]. Probably because of this, our TRs more often received a
three-drug rifampin-sparing regimen and had lengthier treat-
ments than patients from the general population. The recom-
mendations concerning rifampin as a part of tuberculosis
treatment are controversial, although most of the current
guidelines favour a rifamycin-containing regimen [11,13,14].
In this series, antituberculous drug-induced toxicity was
more frequent in TRs. There were no signiﬁcant differences in
the percentage of hepatotoxicity between the two groups,
possibly because the deﬁnition of hepatotoxicity was stricter
than in previous reports, the small number of liver transplant
recipients (in whom hepatotoxicity is more common), or the
use of rifampin-free regimens.
Having more organs with tuberculosis involvement, rather
than patient characteristics related to age, Charlson score, or
transplantation, was a predictor of tuberculosis-related mor-
tality. The risk of disseminated tuberculosis is higher among
patients with underlying conditions and impaired immunity;
accordingly, in our study, TRs had more organs with tubercu-
losis involvement. We hypothesize that the delay in diagnosing
tuberculosis in TRs means that more organs are involved by the
time when the ﬁnal diagnosis is made, which is associated with
greater tuberculosis-related mortality.
The ﬁrst limitation of this study is its retrospective design.
Also, although this is one of the largest single-centre series of
TRs with culture-positive tuberculosis to date [3,7–9], com-
parisons were made on a small sample, with a high risk of beta
error (leading to no differences between the compared pop-
ulations). The absence of signiﬁcant differences between the
populations (for drug-related hepatotoxicity or mortality)
should therefore be interpreted with caution. The non-
homogeneity of the transplanted population, including all
types of organ and haematopoietic stem cell transplantation, is a
limitation. Although most patients diagnosed with tuberculosis
in the area were referred to our centre for treatment, we
cannot completely exclude a referral bias in the control cohort.
Additionally, our ﬁndings may not be generalizable to countries
with different incidence rates of tuberculosis.
Our study demonstrates that the manifestations of tuber-
culosis in TRs differ from those in normal hosts. Post-transplant
tuberculosis resists timely diagnosis, and is associated with a
higher risk of death before a diagnosis is reached. The higher
tuberculosis-related mortality among TRs may be a result ofious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 651–658
CMI Benito et al. Tuberculosis in transplant recipients vs. the general population 657more organs having tuberculosis involvement at diagnosis, and
not transplantation itself, which was not associated with
increased tuberculosis-related mortality. A high index of sus-
picion for tuberculosis and performing diagnosis early and
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